Julia Lake, MD
Internal Medicine · Lebanon, NHNPI 1104203702
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$662
- Insulet Corporation$554
- Sanofi-aventis U.S. LLC$201
- Lifescan, Inc.$181
- Novo Nordisk$176
- Mannkind Corporation$172
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,338100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 28 | $662 |
| Insulet Corporation | 12 | $554 |
| Sanofi-aventis U.S. LLC | 9 | $201 |
| Lifescan, Inc. | 6 | $181 |
| Novo Nordisk | 11 | $176 |
| Mannkind Corporation | 8 | $172 |
| Medtronic | 5 | $167 |
| Dexcom, Inc. | 7 | $155 |
| Amgen(2 entities) | 8 | $141 |
| Radius Health, Inc. | 5 | $132 |
| Antares Pharma, Inc. | 7 | $118 |
| Cequr Corporation | 2 | $100 |
| BETA Bionics, Inc. | 11 | $99 |
| Tandem Diabetes Care, Inc. | 4 | $83 |
| Kyowa Kirin, Inc. | 2 | $45 |
| Sequel Med Tech, LLC | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| AstraZeneca | 2 | $33 |
| Bayer | 2 | $32 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Amryt Pharma Holdings Ltd | 1 | $23 |
| Merck | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| AbbVie | 1 | $18 |
| RGH Enterprises LLC | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Halozyme Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$129
- MOUNJARO$125
- MINIMED 780G$107
How this compares
$3,349 in reported general payments places this provider in the 95th percentile of 504 internal medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 180 | $328,035 |
| OzempicSemaglutide | 192 | $318,315 |
| MounjaroTirzepatide | 168 | $204,476 |
| JardianceEmpagliflozin | 141 | $166,871 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $134,417 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 60 | $69,347 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $62,695 |
| FarxigaDapagliflozin Propanediol | 34 | $36,069 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 41 | $29,626 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 197 | $28,879 |
| RybelsusSemaglutide | 21 | $21,852 |
| VascepaIcosapent Ethyl | 41 | $19,023 |
| Lupron DepotLeuprolide Acetate | 11 | $18,491 |
| JanuviaSitagliptin Phosphate | 17 | $17,040 |
| Novolog FlexpenInsulin Aspart | 63 | $16,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $662 | $536,960366 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $176 | $348,917243 claims |
| Boehringer IngelheimJardiance, Glyxambi | $19 | $173,263152 claims |
| AstraZenecaFarxiga | $33 | $36,06934 claims |
| AbbVieLupron Depot, Synthroid | $18 | $19,71335 claims |
| MerckJanuvia | $22 | $17,04017 claims |
| Antares Pharma, Inc.Xyosted | $118 | $13,19812 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $31 | $4,746381 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 504 internal medicine providers in New Hampshire.
Other internal medicine in Lebanon
- Deborah TepperLebanon$133K
- William MonacoLebanon$97K
- Mary McGowanLebanon$26K
- Daniel FeldmanLebanon$17K
- Amir Soheil TolebeyanLebanon$13K
- Scott RizziLebanon$13K
- Jonathan LurieLebanon$8K
- Lisa AdamsLebanon$4K
- Stephen LiuLebanon$2K
- Lionel LewisLebanon$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.